Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Quoin Pharmaceuticals (QNRX)
NASDAQ:QNRX
RESEARCH TOOLSreports
Quoin Pharmaceuticals (QNRX) Stock Price & Analysis
250 Followers
QNRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.57 - $12.00
Previous Close$0.58
Volume6.31K
Average Volume (3M)52.54K
Market Cap
$2.20M
Enterprise Value$401.28K
Total Cash (Recent Filing)$1.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Aug 15, 2024EPS Estimate
-$0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.54
Shares Outstanding3,979,970
10 Day Avg. Volume47,441
30 Day Avg. Volume52,541
Standard Deviation0.26
R-Squared0.15
Alpha-0.11
Financial Highlights & Ratios
Price to Book (P/B)0.28
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$4.00Price Target Upside589.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Quoin Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe open-label data for QRX003 in treating Netherton Syndrome has shown promising signals of efficacy with no major safety concerns.
Financial StabilityQuoin has sufficient funding into late 2025 and past the Phase 3 readout, ensuring financial stability for ongoing trials.
Product DevelopmentQRX003 may be the first product to both readout a pivotal trial in NS and be approved for the indication.
Bears Say
Operating Expenses1Q24 operating expenses were higher than expected, leading to an increase in the operating expense estimates for 2024 and 2025.
Price TargetAnalysts have reduced the 12-month price target for Quoin from $15 to $4 due to updated estimates, timelines, and potential dilution from capital raises.
Product LaunchLaunch estimates for QRX003 in Netherton Syndrome have been conservatively pushed back to 2026, affecting the stock price target.
---
Ownership Overview
<0.01% Insiders
<0.01% Mutual Funds
2.44% Other Institutional Investors
97.56% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
QNRX FAQ
What was Quoin Pharmaceuticals’s price range in the past 12 months?
Quoin Pharmaceuticals lowest stock price was $0.57 and its highest was $12.00 in the past 12 months.
What is Quoin Pharmaceuticals’s market cap?
Currently, no data Available
When is Quoin Pharmaceuticals’s upcoming earnings report date?
Quoin Pharmaceuticals’s upcoming earnings report date is Aug 15, 2024 which is in 38 days.
How were Quoin Pharmaceuticals’s earnings last quarter?
Quoin Pharmaceuticals released its earnings results on May 09, 2024. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.76 by -$0.35.
Is Quoin Pharmaceuticals overvalued?
According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued.
Does Quoin Pharmaceuticals pay dividends?
Quoin Pharmaceuticals does not currently pay dividends.
What is Quoin Pharmaceuticals’s EPS estimate?
Quoin Pharmaceuticals’s EPS estimate is -$0.63.
How many shares outstanding does Quoin Pharmaceuticals have?
Quoin Pharmaceuticals has 3,979,970 shares outstanding.
What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?
Quoin Pharmaceuticals reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.76. Following the earnings report the stock price went up 1.266%.
Which hedge fund is a major shareholder of Quoin Pharmaceuticals?
Currently, no hedge funds are holding shares in QNRX
---
Quoin Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (589.42% Upside)
$4.00 (589.42% Upside)
Insider Transactions
Sold Shares
Worth $216.8 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.12%
12-Months-Change
Fundamentals
Return on Equity
-84.12%
Trailing 12-Months
Asset Growth
-12.61%
Trailing 12-Months
Company Description
Quoin Pharmaceuticals
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. Cellect Biotechnology was founded by Kasbian Nuriel Chirich, Shai Yarkoni and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.
---
QNRX Stock 12 Month Forecast
Average Price Target
$4.00
▲(589.42% Upside)
Technical Analysis
Best Analysts Covering QNRX
1 Year
1 Year Success Rate
0/16 ratings generated profit
1 Year Average Return
-75.63%
reiterated a buy rating 27 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -75.63% per trade.
---